<DOC>
	<DOCNO>NCT00320359</DOCNO>
	<brief_summary>Evaluation intravenous Topotecan + Cisplatin potential new standard care 1st line Small Cell Lung Cancer</brief_summary>
	<brief_title>Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st Line Extensive Disease Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Evaluable extensive small cell lung cancer , extensive disease . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; 2 . Life expectancy &gt; 3 month . Fit receive treatment . No prior chemotherapy . Written informed consent . Extensive disease treatable radiotherapy . Past current history malignant disease . Prior chemotherapy . Pregnancy , lactate lack effective contraception . Concurrent severe medical problem small cell lung cancer . Patients central nervous system metastases receive 12 mg /day dexamethasone equivalent control symptom .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>First-line Cisplatin</keyword>
	<keyword>Small Cell Lung Cancer</keyword>
	<keyword>topotecan</keyword>
	<keyword>etoposide</keyword>
	<keyword>Extensive Disease</keyword>
</DOC>